scholarly journals Evaluation of Multi-Layered Pancreatic Islets and Adipose-Derived Stem Cell Sheets Transplanted on Various Sites for Diabetes Treatment

Cells ◽  
2020 ◽  
Vol 9 (9) ◽  
pp. 1999
Author(s):  
Yu Na Lee ◽  
Hye-Jin Yi ◽  
Yang Hee Kim ◽  
Song Lee ◽  
Jooyun Oh ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Cell Transplantation ◽  
Graft Survival ◽  
Glucose Control ◽  
Islet Cell ◽  
Human Islets ◽  
Islet Cell Transplantation ◽  
Cell Sheets ◽  
Peritoneal Surface

Islet cell transplantation is considered an ideal treatment for insulin-deficient diabetes, but implantation sites are limited and show low graft survival. Cell sheet technology and adipose-derived stem cells (ADSCs) can be useful tools for improving islet cell transplantation outcomes since both can increase implantation efficacy and graft survival. Herein, the optimal transplantation site in diabetic mice was investigated using islets and stem cell sheets. We constructed multi-layered cell sheets using rat/human islets and human ADSCs. Cell sheets were fabricated using temperature-responsive culture dishes. Islet/ADSC sheet (AI sheet) group showed higher viability and glucose-stimulated insulin secretion than islet-only group. Compared to islet transplantation alone, subcutaneous AI sheet transplantation showed better blood glucose control and CD31+ vascular traits. Because of the adhesive properties of cell sheets, AI sheets were easily applied on liver and peritoneal surfaces. Liver or peritoneal surface grafts showed better glucose control, weight gain, and intraperitoneal glucose tolerance test (IPGTT) profiles than subcutaneous site grafts using both rat and human islets. Stem cell sheets increased the therapeutic efficacy of islets in vivo because mesenchymal stem cells enhance islet function and induce neovascularization around transplanted islets. The liver and peritoneal surface can be used more effectively than the subcutaneous site in future clinical applications.

scholarly journals Bioengineered stem cells as an alternative for islet cell transplantation

2015 ◽  
Vol 5 (1) ◽  
pp. 1 ◽  
Author(s):  
Sarah J Moore ◽  
Boris L Gala-Lopez ◽  
Andrew R Pepper ◽  
Rena L Pawlick ◽  
AM James Shapiro
Keyword(s):  
Stem Cells ◽  
Cell Transplantation ◽  
Islet Cell ◽  
Islet Cell Transplantation

scholarly journals A Comparison Between Islet And Stem Cell Transplantation For Treatment Of Type 1 Diabetes Mellitus: A Systematic Review

2016 ◽  
Vol 1 (2) ◽  
Keyword(s):  
Stem Cell ◽  
Glycemic Control ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Islet Cell ◽  
Islet Cell Transplantation ◽  
Insulin Independence ◽  
Current Standard ◽  
Current Standard Treatment

Introduction: The incidence of type 1 Diabetes Mellitus (T1DM) has been increasing rapidly worldwide in the past decade. The current standard treatment is exogenous insulin therapy, however, this procedure is highly associated with poor glycemic control that may lead to life-threatening hypoglycemic episodes. Cellular-based therapy for T1DM has been recently developed, making it pertinent to compare the effectiveness between two most anticipated breakthroughs: islet cell and stem cell transplantation, in order to determine which procedure is more effective. Methods: A comprehensive digital literature search was performed using PubMed and Ovid Medline for primary research studies published between Jan 2000 – Nov 2015. Relevant cohort, case-control, case series, and in vivo studies were included. The abstracts and full text of the retrieved articles were scanned for potential studies that fulfilled the inclusion criterias. The quality assessment of studies were conducted using ARRIVE, NOS, and MINORS. Results: Nineteen primary research studies met the inclusion criterias and were assessed for the review. Eleven out of 19, were considered as high-quality, while the rest were moderate-quality. The studies generally reported the insulin independence, graft functionality, and glycemic control. The insulin-independent period for islet cell tranplantation was proven to be longer compared to stem cell transplantation with better glycemic control. Stem cells were successfully differentiated into glucoseresponsive insulin-producing cells, that also released glucagon and somatostatin. Discussion: The majority of the included studies were using the same outcome measures which allow a more comprehensive comparison to be conducted. Based on the assessment, islet cell transplantation is currently better. This treatment was found to lead to significant improvements in insulin independence and glycemic control observed through insulin-free period, HbA1c, blood glucose, and C-peptide serum measurement. On the other hand, certain challenges – such as donor shortage and poor engraftment - hinders the widespread application of the treatment. Therefore, stem cell transplantation is thought to possibly be replacing islet cell transplantation in the future. Stem cells had successfully been differentiated into β-like cells that were not only producing insulin, but also glucagon and somatostatin, as well as acting in glucose-stimulated manner, imitating the physiologic mechanism of β-cells. Conclusion: It is conclusive that islet stem cell transplantation was proven to perform relatively better in terms of insulin independence and glycemic control compared to stem cell transplantation for treating T1DM. Both cellular-based treatments provided relatively better glycemic control compared to the current standard treatment, exogenous insulin therapy. All the studies have reported that both treatments lead to substantial improveent between pre-and post-transplantation periods. Stem cell transplantation was also proven to have unlimited potentials to be the future solution for T1DM. Although, there was limited studies on human subjects, but based on the current available studies, the results were quite conclusive.

Stem Cell Transplantation: A Promising Therapy for Spinal Cord Injury

2020 ◽  
Vol 15 (4) ◽  
pp. 321-331 ◽  
Author(s):  
Zhe Gong ◽  
Kaishun Xia ◽  
Ankai Xu ◽  
Chao Yu ◽  
Chenggui Wang ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Therapeutic Potential ◽  
Embryonic Stem ◽  
Current Status ◽  
Cord Injury

Spinal Cord Injury (SCI) causes irreversible functional loss of the affected population. The incidence of SCI keeps increasing, resulting in huge burden on the society. The pathogenesis of SCI involves neuron death and exotic reaction, which could impede neuron regeneration. In clinic, the limited regenerative capacity of endogenous cells after SCI is a major problem. Recent studies have demonstrated that a variety of stem cells such as induced Pluripotent Stem Cells (iPSCs), Embryonic Stem Cells (ESCs), Mesenchymal Stem Cells (MSCs) and Neural Progenitor Cells (NPCs) /Neural Stem Cells (NSCs) have therapeutic potential for SCI. However, the efficacy and safety of these stem cellbased therapy for SCI remain controversial. In this review, we introduce the pathogenesis of SCI, summarize the current status of the application of these stem cells in SCI repair, and discuss possible mechanisms responsible for functional recovery of SCI after stem cell transplantation. Finally, we highlight several areas for further exploitation of stem cells as a promising regenerative therapy of SCI.

Islet cell transplantation for the treatment of type 1 diabetes in the USA

2008 ◽  
Vol 16 (2) ◽  
pp. 118-123 ◽  
Author(s):  
Tetsuya Ikemoto ◽  
Hirofumi Noguchi ◽  
Masayuki Shimoda ◽  
Bashoo Naziruddin ◽  
Andrew Jackson ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Transplantation ◽  
Islet Cell ◽  
Islet Cell Transplantation ◽  
The Usa

scholarly journals The Transplantation Resistance of Type II Diabetes Mellitus Adipose-Derived Stem Cells Is Due to G6PC and IGF1 Genes Related to the FoxO Signaling Pathway

2021 ◽  
Vol 22 (12) ◽  
pp. 6595
Author(s):  
Michiko Horiguchi ◽  
Yuya Turudome ◽  
Kentaro Ushijima
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Signaling Pathway ◽  
Cell Transplantation ◽  
Type Ii ◽  
Lower Performance ◽  
Foxo Signaling Pathway ◽  
Healthy Persons

In cases of patients with rapidly progressive diabetes mellitus (DM), autologous stem cell transplantation is considered as one of the regenerative treatments. However, whether the effects of autonomous stem cell transplantation on DM patients are equivalent to transplantation of stem cells derived from healthy persons is unclear. This study revealed that adipose-derived mesenchymal stem cells (ADSC) derived from type II DM patients had lower transplantation efficiency, proliferation potency, and stemness than those derived from healthy persons, leading to a tendency to induce apoptotic cell death. To address this issue, we conducted a cyclopedic mRNA analysis using a next-generation sequencer and identified G6PC3 and IGF1, genes related to the FoxO signaling pathway, as the genes responsible for lower performance. Moreover, it was demonstrated that the lower transplantation efficiency of ADSCs derived from type II DM patients might be improved by knocking down both G6PC3 and IGF1 genes. This study clarified the difference in transplantation efficiency between ADSCs derived from type II DM patients and those derived from healthy persons and the genes responsible for the lower performance of the former. These results can provide a new strategy for stabilizing the quality of stem cells and improving the therapeutic effects of regenerative treatments on autonomous stem cell transplantation in patients with DM.

Sign in / Sign up

Export Citation Format

Share Document